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Increased utilization of cardiovascular implantable electronic devices (CIED) has seen a cor-
responding rise in related infections. Non-tuberculosis mycobacteria (NTM) are rarely the
cause. Treatment involves susceptibilities, antimicrobials, and device removal. This study
presents a patient who underwent a biventricular implantable cardioverter defibrillator
upgrade with a multi-drug resistant Mycobacterium fortuitum located at the pocket site
and a lead infection.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Case report
A 56-year-old African American man with a history of non-
ischemic cardiomyopathy, biventricular failure with left ven-
tricular ejection fraction of 15%, left ventricular thrombus
on chronic anticoagulation meds, Mobitz type II and complete
heart block status post a permanent pacemaker, with cocaine
and alcohol use, was transferred to the coronary intensive
care unit after an elective right atrial lead revision 3 years
after the original device implant. Four months previous, he
had undergone a biventricular implantable cardioverter defi-
brillator (BiV ICD) upgrade with the insertion of a new right-African Society for Myco
ent of Cardiology, Virgi
9989 (Office), mobile: +1
u).ventricular (RV) ICD lead and new left ventricular lead. On a
follow-up device check, the chest radiograph showed a slight
retraction of the right atrial (RA) lead and upon interro-
gation revealed high pacing impedance, decreased P-wave
sensing and markedly increased pacing threshold. The
patient then underwent an RA lead revision, during which
an area seen under the RA lead sleeve suggested purulent
discharge; cultures were obtained and sent to the lab. A small
hematoma was noted at the pacer pocket post-op day 1 of the
revision, and observation in the hospital was recom-
mended though the patient requested to be discharged.
During a follow-up appointment at another medical center,bacteriology. All rights reserved.
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sub-therapeutic, after which the patient was started on
Enoxaparin. Eight days later, the patient presented with pain
and swelling at the BiV ICD pocket site. The hematoma at the
BiV ICD site had enlarged, as well as superficial skin bullae
(initial aspirate cultures with no growth) formed at the
incision site. He underwent a hematoma evacuation and
was treated empirically with Cephalexin for 2 weeks. After
completing the oral antibiotic course, he presented again
with worsening pain and wound dehiscence, with exposure
of the BiV ICD generator, and serosanguineous discharge.
No fever or leukocytosis was noted. The patient was readmit-
ted for device and lead extraction and started empirically on
Vancomycin. He underwent lead extraction 5· with place-
ment of a temporary externalized pacemaker. The RV ICD
lead culture grew 5 colonies of Mycobacterium fortuitum; RA
pacer lead, 10 colonies of M. fortuitum; tissue culture of chest
wall, 2 colonies of M. fortuitum; pacer pocket swab, high
growth ofM. fortuitum; and chest wall swab, moderate growth
of acid fast bacillus (AFB). AFB blood cultures returned no
growth for 8 weeks. Initial blood cultures with no growth.
The transthoracic echocardiogram showed no obvious
vegetations or evidence of endocarditis. The patient never
confirmed whether he might have showered or contaminated
the incision pocket with water. He was initially treated
with Imipenem, Clarithromycin and Moxifloxacin; the latter
of which switched to Meropenem, Linezolid and Doxycycline
owing to less QT prolongation effects. Final culture
sensitivities from the left pacer pocket revealed resistance
to Amikacin, Macrolides, Doxycycline and Linezolid; sensitive
to Tobramycin, Fluoroquinolones and Imipenem. The remain-
der of his hospital course was complicated by a right middle
cerebral artery (MCA) infarct with cerebral edema andmidline
shift, left superior parietal stroke, seizures, coagulase-
negative staphylococci (CoNS) bacteremia, acute respiratory
failure and eventual withdrawal of care with subsequent
death.
Discussion
Cardiovascular implantable electronic devices (CIED) have
been increasingly utilized over the years in the management
of various cardiovascular diseases. Between 1997 and 2004,
PPM implantation rates have increased by 19%; and ICDs by
60% [1]. Along with the rise of the utilization of CIEDs, CIED
infection rates and hospitalizations relating to CIED infec-
tions have also risen [2–5]. PPM infection rates have been pre-
viously reported to range between 0.13% and 19.9%; ICD
infection rates have been estimated to be 0.5% for pectoral de-
vices and 3.2% for abdominal devices. Staphylococcus species
and CoNS are the most commonly involved in CIED infec-
tions. Non-Candidal fungi and NTM are rarely the cause of
CIED infections [6]. To date, review of the literature has re-
vealed 10 cases of rapidly growing NTM (M. fortuitum, M.
abscessus, M. chelonae, M. margeritense, M. avium complex) as
pathogens involved in CIED infections [7–15]. NTM CIED infec-
tions most commonly present with purulent discharge and
pain at the pocket site and fever, and involve the generatorpocket site, and epicardial and transvenous leads. NTM CIED
infections may also result in endocarditis [16–18]. Treatment
of rapidly growing NTM CIED infections are based on culture
susceptibilities and usually involve a combination of Macro-
lides, Fluoroquinolones, and amino glycosides for a duration
of 6 weeks up to 6 months [18]. The majority of cured cases
of NTM device infections have involved removal of the device,
along with lead extraction [5–15]. Pastor et al. reported a cured
case of antimicrobial therapy with a Macrolide and Fluoro-
quinolone for 6 weeks [12]. Manifestation of NTM CIED infec-
tions from the initial date of device implantation to diagnosis
has ranged from 13 days to 20 years with 6 months being the
most common. This study presents a patient who underwent
a BiV upgrade two years after initial device implant and was
discovered to have a multi-drug resistant, rapidly growing
M. fortuitum generator at the pocket site and lead infection,
followed by CoNS bacteremia.
According to the Infectious Disease Society of America
(IDSA) Emerging Infections Network (EIN), reports of myco-
bacterial infections have been increasing. Epidemiological
data is lacking on NTM infections overall since the latter are
not reported to public health departments. Mycobacteria
species are found in soil, dust, water, rocks and can survive
extreme pH, temperature and nutrient conditions. NTM are
found in aquatic systems and have a high incidence in the
United States’ mid-Atlantic and southeastern areas due to
their presence in the soil. M. fortuitum, M. chelonae,
M. abscessus have been found in cold water systems and form
biofilms for survival. Rapidly growing NTM has been shown to
be resistant to disinfectants, such as chlorine, organomercu-
rials and alkaline glutaraldehydes [17–19]. M. fortuitum has
been involved in a pseudo-outbreak on a human
immunodeficiency virus (HIV) ward resulting from a
contaminated ice machine, with the mechanism involving
colonization of the respiratory tract. M. fortuitum commonly
affect immunocompromised hosts and has been reported to
be the pathogen in Nosocomial and catheter-related, suture
material, mammoplasty, sternal wound, skin and soft tissue,
and intrathecal drug delivery device infections [11–23].
Misidentification of M. fortuitum for gram-positive bacilli,
Nocardia spp., Rhodococcus spp., and Corynebacterium spp. has
occurred. The rise of rapidly growing NTM CIED infections
over the years proposes an alternate, less common pathogen
as the etiology. NTM should be considered in cases in which
the host is immunocompromised or with a propensity for
slow wound healing, as well as considered when a surgical
site has to be re-opened and re-manipulated. Treatment of
NTM CIED infections is case-dependent, involves multiple
broad antimicrobials and is dependent on susceptibilities.
The case presented herein exemplified the importance of
considering multidrug resistant NTM early in the course of
a CIED infection and the poor outcomes that may be
associated with these infections.Conflict of interest
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